Laura Butragueño-Laiseca1,2,3,4, Iñaki F Troconiz5,6, Santiago Grau7, Nuria Campillo7, Xandra García8, Belén Padilla9, Sarah N Fernández1,2,3,4, María José Santiago1,2,3,4. 1. Pediatric Intensive Care Unit, Hospital General Universitario Gregorio Marañón, 28009 Madrid, Spain. 2. Gregorio Marañón Health Research Institute (IISGM), 28007 Madrid, Spain. 3. Pediatrics Department, Universidad Complutense de Madrid, 28040 Madrid, Spain. 4. Maternal and Child Health and Development Research Network (REDSAMID), Institute of Health Carlos III, 28029 Madrid, Spain. 5. Pharmacometrics & Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, 28027 Pamplona, Spain. 6. IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain. 7. Pharmacy Department, Hospital del Mar, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain. 8. Pharmacy Department, Hospital General Universitario Gregorio Marañón, 28009 Madrid, Spain. 9. Clinical Microbiology Department, Hospital General Universitario Gregorio Marañón, 28009 Madrid, Spain.
Abstract
Background: Ceftolozane-tazobactam is a new antibiotic against multidrug-resistant pathogens such as Pseudomonas aeruginosas. Ceftolozane-tazobactam dosage is still uncertain in children, especially in those with renal impairment or undergoing continuous renal replacement therapy (CRRT). Methods: Evaluation of different ceftolozane-tazobactam dosing regimens in three critically ill children. Ceftolozane pharmacokinetics (PK) were characterized by obtaining the patient's specific parameters by Bayesian estimation based on a population PK model. The clearance (CL) in patient C undergoing CRRT was estimated using the prefilter, postfilter, and ultrafiltrate concentrations simultaneously. Variables such as blood, dialysate, replacement, and ultrafiltrate flow rates, and hematocrit were integrated in the model. All PK analyses were performed using NONMEM v.7.4. Results: Patient A (8 months of age, 8.7 kg) with normal renal function received 40 mg/kg every 6 h: renal clearance (CLR) was 0.88 L/h; volume of distribution (Vd) Vd1 = 3.45 L, Vd2 = 0.942 L; terminal halflife (t1/2,β) = 3.51 h, dosing interval area under the drug concentration vs. time curve at steady-state (AUCτ,SS) 397.73 mg × h × L-1. Patient B (19 months of age, 11 kg) with eGFR of 22 mL/min/1.73 m2 received 36 mg/kg every 8 h: CLR = 0.27 L/h; Vd1 = 1.13 L; Vd2 = 1.36; t1/2,β = 6.62 h; AUCSS 1481.48 mg × h × L-1. Patient C (9 months of age, 5.8 kg), with severe renal impairment undergoing CRRT received 30 mg/kg every 8 h: renal replacement therapy clearance (CLRRT) 0.39 L/h; Vd1 = 0.74 L; Vd2= 1.17; t 1/2,β = 3.51 h; AUCτ,SS 448.72 mg × h × L-1. No adverse effects attributable to antibiotic treatment were observed. Conclusions: Our results suggest that a dose of 35 mg/kg every 8 h can be appropriate in critically ill septic children with multi-drug resistance Pseudomonas aeruginosa infections. A lower dose of 10 mg/kg every 8 h could be considered for children with severe AKI. For patients with CRRT and a high effluent rate, a dose of 30 mg/kg every 8 h can be considered.
Background: Ceftolozane-tazobactam is a new antibiotic against multidrug-resistant pathogens such as Pseudomonas aeruginosas. Ceftolozane-tazobactam dosage is still uncertain in children, especially in those with renal impairment or undergoing continuous renal replacement therapy (CRRT). Methods: Evaluation of different ceftolozane-tazobactam dosing regimens in three critically illchildren. Ceftolozane pharmacokinetics (PK) were characterized by obtaining the patient's specific parameters by Bayesian estimation based on a population PK model. The clearance (CL) in patient C undergoing CRRT was estimated using the prefilter, postfilter, and ultrafiltrate concentrations simultaneously. Variables such as blood, dialysate, replacement, and ultrafiltrate flow rates, and hematocrit were integrated in the model. All PK analyses were performed using NONMEM v.7.4. Results:Patient A (8 months of age, 8.7 kg) with normal renal function received 40 mg/kg every 6 h: renal clearance (CLR) was 0.88 L/h; volume of distribution (Vd) Vd1 = 3.45 L, Vd2 = 0.942 L; terminal halflife (t1/2,β) = 3.51 h, dosing interval area under the drug concentration vs. time curve at steady-state (AUCτ,SS) 397.73 mg × h × L-1. Patient B (19 months of age, 11 kg) with eGFR of 22 mL/min/1.73 m2 received 36 mg/kg every 8 h: CLR = 0.27 L/h; Vd1 = 1.13 L; Vd2 = 1.36; t1/2,β = 6.62 h; AUCSS 1481.48 mg × h × L-1. Patient C (9 months of age, 5.8 kg), with severe renal impairment undergoing CRRT received 30 mg/kg every 8 h: renal replacement therapy clearance (CLRRT) 0.39 L/h; Vd1 = 0.74 L; Vd2= 1.17; t 1/2,β = 3.51 h; AUCτ,SS 448.72 mg × h × L-1. No adverse effects attributable to antibiotic treatment were observed. Conclusions: Our results suggest that a dose of 35 mg/kg every 8 h can be appropriate in critically ill septicchildren with multi-drug resistance Pseudomonas aeruginosainfections. A lower dose of 10 mg/kg every 8 h could be considered for children with severe AKI. For patients with CRRT and a high effluent rate, a dose of 30 mg/kg every 8 h can be considered.
Authors: Kajal B Larson; Yogesh T Patel; Susan Willavize; John S Bradley; Elizabeth G Rhee; Luzelena Caro; Matthew L Rizk Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: María Martín-Cazaña; Santiago Grau; Cristina Epalza; Patricia Brañas; Marta Flores; Marta Olmedilla; Daniel Blázquez-Gamero Journal: J Paediatr Child Health Date: 2019-02-08 Impact factor: 1.954
Authors: Matthew Rawlins; Vesa Cheng; Edward Raby; John Dyer; Adrian Regli; Paul Ingram; Brett C McWhinney; Jacobus P J Ungerer; Jason A Roberts Journal: Chemotherapy Date: 2018-10-10 Impact factor: 2.544
Authors: John S Bradley; Jocelyn Y Ang; Antonio C Arrieta; Kajal B Larson; Matthew L Rizk; Luzelena Caro; Shan Yang; Brian Yu; Matthew G Johnson; Elizabeth G Rhee Journal: Pediatr Infect Dis J Date: 2018-11 Impact factor: 2.129
Authors: Astrid Broeker; Matthias G Vossen; Florian Thalhammer; Steven C Wallis; Jeffrey Lipman; Jason A Roberts; Sebastian G Wicha Journal: Pharm Res Date: 2020-05-14 Impact factor: 4.200
Authors: Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton Journal: Clin Pharmacokinet Date: 2021-11-30 Impact factor: 6.447
Authors: Gideon Stitt; Samuel Dubinsky; Andrea Edginton; Yuan-Shung V Huang; Athena F Zuppa; Kevin Watt; Kevin Downes Journal: Front Pediatr Date: 2022-05-12 Impact factor: 3.569